Rani Therapeutics Holdings (RANI) Hisse Özeti
Rani Therapeutics Holdings, Inc. klinik aşamada bir biyoterapötik şirketi olarak faaliyet göstermekte ve Amerika Birleşik Devletleri'nde hastalar, doktorlar ve sağlık sistemleri için ağrılı enjeksiyonlara alternatif olarak biyolojik ve ilaçların ağızdan verilmesini sağlayacak teknolojilere odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 1/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
+ 1 daha fazla risk
RANI Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rani Therapeutics Holdings, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$0.65 |
| 52 Haftanın En Yüksek Seviyesi | US$3.87 |
| 52 Haftanın En Düşük Seviyesi | US$0.39 |
| Beta | 0.80 |
| 1 Aylık Değişim | -14.62% |
| 3 Aylık Değişim | -32.40% |
| 1 Yıllık Değişim | 52.13% |
| 3 Yıllık Değişim | -84.84% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -94.10% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 01
RANI: Cash Raise And Nasdaq Compliance Efforts Will Drive Future Upside
Analysts have reduced their price target for Rani Therapeutics Holdings from $9.25 to $7.50, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E levels in their valuation models. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings received a notice from Nasdaq on May 11, 2026, that its Class A common stock no longer meets the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market, with a 180 day window until November 9, 2026, to regain compliance.
Anlatı Güncellemesi • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.Anlatı Güncellemesi • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.Recent updates
Anlatı Güncellemesi • Jul 01
RANI: Cash Raise And Nasdaq Compliance Efforts Will Drive Future Upside
Analysts have reduced their price target for Rani Therapeutics Holdings from $9.25 to $7.50, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E levels in their valuation models. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings received a notice from Nasdaq on May 11, 2026, that its Class A common stock no longer meets the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market, with a 180 day window until November 9, 2026, to regain compliance.Anlatı Güncellemesi • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.Anlatı Güncellemesi • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.Anlatı Güncellemesi • Apr 27
RANI: Obesity Capsule Trial Progress Will Support Strong Future Upside Potential
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing a balance between slightly adjusted revenue growth, profit margin expectations, and a modestly lower future P/E assumption. Valuation Changes Fair Value: $11.00 remains unchanged, indicating no adjustment to the core valuation estimate.Anlatı Güncellemesi • Apr 12
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts maintained their $11.00 price target for Rani Therapeutics Holdings, citing only marginal tweaks in their long term growth and P/E assumptions rather than a change in their overall view of the company. Valuation Changes Fair Value: $11.00 remains unchanged, with no adjustment to the headline valuation figure.
Yeni Anlatı • Mar 31
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 29
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts have kept their price target for Rani Therapeutics Holdings steady at $11.00, reflecting updated assumptions for revenue growth, profit margin, and future P/E that broadly balance each other out in their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, for the treatment of obesity (Key Developments).Analiz Makalesi • Mar 28
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Anlatı Güncellemesi • Mar 10
RANI: Obesity Capsule Trial Progress Will Support A More Optimistic Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing updated assumptions about very large revenue growth expectations, a stronger projected profit margin near 21%, and a higher anticipated future P/E multiple as key drivers within their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).Anlatı Güncellemesi • Feb 24
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing largely steady assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E as reasons to maintain their existing view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist, for potential obesity treatment (company announcement).Anlatı Güncellemesi • Feb 09
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts kept their fair value estimate for Rani Therapeutics Holdings steady at US$11.00, citing offsetting tweaks to key assumptions such as a slightly higher discount rate, a modestly different revenue growth outlook, a small adjustment to projected profit margins, and a marginally lower future P/E. What's in the News Rani Therapeutics Holdings started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist being developed for obesity, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in single and multiple dosing.Anlatı Güncellemesi • Jan 25
RANI: Obesity Trial Progress And Index Inclusion Will Support A Stronger Outlook
Analysts have kept their US$11.00 price target for Rani Therapeutics Holdings unchanged, citing only fine tuned inputs in discount rate, revenue growth, profit margin and future P/E assumptions that collectively do not shift their overall valuation view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial of RT-114, an oral RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).Anlatı Güncellemesi • Jan 11
RANI: Future Obesity Trial Progress Will Support A Stronger Bullish Outlook
Analysts have raised their fair value estimate for Rani Therapeutics Holdings from US$9.00 to US$11.00. They cite updated assumptions on revenue growth, profit margin and a higher future P/E multiple as the main factors behind the new price target.Anlatı Güncellemesi • Dec 26
RANI: Collaboration With Chugai And Cash Infusion Will Drive Future Upside
Analysts have nudged their price target for Rani Therapeutics Holdings slightly higher to 9.25 dollars, reflecting modestly improved long term growth and profitability assumptions despite largely unchanged valuation inputs. What's in the News Rani Therapeutics was added to the NASDAQ Biotechnology Index, increasing its visibility among biotech investors (Index Constituent Adds).Anlatı Güncellemesi • Dec 11
RANI: Licensing Deal And Capital Raise Will Support Future Platform Upside
Analysts have modestly reaffirmed their outlook on Rani Therapeutics Holdings, keeping the price target effectively unchanged at approximately 9.25 dollars. They continue to view the company’s long term revenue growth and margin profile as supportive of its elevated future valuation multiple.Anlatı Güncellemesi • Nov 27
RANI: Recent Licensing Agreement Will Drive Platform Expansion and Revenue Potential
Analysts have lowered their price target for Rani Therapeutics Holdings from $9.50 to $9.25. They cited updated estimates of growth and profit margin impacts on future valuation.Seeking Alpha • Nov 05
Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks
Summary Rani Therapeutics Holdings, Inc. targets a new potential oral delivery of biologic drugs via the RaniPill. This could eventually replace injections and improve patient adherence. Their pipeline has RT-102 (osteoporosis), RT-111 (psoriasis), and RT-114 (obesity with ProGen). Interestingly, RANI anticipates initiating RT-114’s Phase 1 trials during 2H2025. So, their IP remains clearly in the very early stages for now. Still, their partnership with Chugai added much upfront cash payments and up to $175 million milestone payments. Overall, RANI stock still appears somewhat overvalued after the recent equity raises. And their IP is highly speculative. So, I feel a neutral Hold makes sense for now. Read the full article on Seeking AlphaAnlatı Güncellemesi • Nov 04
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Analysts have raised their price target for Rani Therapeutics Holdings from $9.00 to $9.50, citing modest adjustments in future earnings expectations and profit margin outlook. What's in the News Rani Therapeutics Holdings announced it will present preclinical data on its RaniPill capsule at ObesityWeek 2025.Anlatı Güncellemesi • Oct 21
Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update
Analysts have increased their price target for Rani Therapeutics Holdings from $7.75 to $9.00. They cite recalibrated growth projections and adjusted profit expectations as key factors behind the change.Anlatı Güncellemesi • Aug 15
RT-114 And Pill Technology Will Transform Obesity Treatments
Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75. What's in the News Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.
Yeni Anlatı • Apr 09
RT-114 And Pill Technology Will Transform Obesity Treatments
RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue.Analiz Makalesi • Feb 07
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Mar 20
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 08
Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Rani Therapeutics (NASDAQ:RANI) enters a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the company’s drug pipeline. Under the loan agreement, company will receive $15M of the initial $30M tranche at closing, with the remaining $15M available for draw at the company’s discretion in Q4 2022. Company has the right to request an additional $15M of funds in the future if certain conditions and milestones are met. Interest at a variable rate equal to the greater of (1) prime, plus 5.6% and (2) 10.35%Analiz Makalesi • Feb 13
We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Hissedar Getirileri
| RANI | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | -8.5% | -5.3% | 0.2% |
| 1Y | 52.1% | 44.2% | 19.6% |
Getiri vs. Endüstri: RANI geçen yıl % 44.2 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: RANI geçen yıl % 19.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| RANI volatility | |
|---|---|
| RANI Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: RANI hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: RANI 'nin haftalık oynaklığı son bir yılda 38% dan 13% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2012 | 70 | Talat Imran | www.ranitherapeutics.com |
Rani Therapeutics Holdings, Inc., klinik aşamadaki bir biyoterapötik şirketi olarak faaliyet göstermekte olup, ABD’de hastalar, hekimler ve sağlık sistemleri için ağrılı enjeksiyonlara alternatif olarak biyolojik ilaçların ve ilaçların ağız yoluyla verilmesini mümkün kılan teknolojilere odaklanmaktadır. Şirket, oligonükleotidler, peptitler, proteinler ve antikorlar dahil olmak üzere çeşitli ilaç maddelerini iletmek için ilaç türünden bağımsız bir oral uygulama platformu olan RaniPill kapsülünü geliştirmektedir. Ürün portföyünde, romatoid artrit tedavisi için preklinik çalışmalar aşamasında olan bir anti-TNF-alfa antikoru olan RT-105; obezite tedavisi için keşif aşamasında olan RT-116; nadir hastalıklar için RT-117; ve çeşitli enflamatuar durumların tedavisi için bir ustekinumab biyobenzeri olan RT-111 yer almaktadır.
Rani Therapeutics Holdings, Inc. Temel Bilgiler Özeti
| RANI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$78.37m |
| Kazançlar(TTM) | -US$29.44m |
| Gelir(TTM) | US$3.17m |
20.5x
P/S Oranı-2.2x
F/K OranıRANI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| RANI gelir tablosu (TTM) | |
|---|---|
| Gelir | US$3.17m |
| Gelir Maliyeti | US$0 |
| Brüt Kâr | US$3.17m |
| Diğer Giderler | US$32.61m |
| Kazançlar | -US$29.44m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.29 |
| Brüt Marj | 100.00% |
| Net Kâr Marjı | -929.06% |
| Borç/Özkaynak Oranı | 0% |
RANI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/14 09:26 |
| Gün Sonu Hisse Fiyatı | 2026/07/14 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Rani Therapeutics Holdings, Inc. 9 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Mitchell Kapoor | H.C. Wainwright & Co. |